Daily GLP-1 tablets are widening the market for obesity treatments and attracting new patients.
The first oral Wegovy from Novo Nordisk achieved a rapid US launch and strong early demand.
Patients switching from injections report easier use and more stable appetite control.
Pills are cheaper, need no refrigeration and appeal to people who avoid needles.
The sector could reach $200bn by the early 2030s as global obesity rises.
Health systems may also find tablets more cost-effective than weekly jabs.
However, side-effects, supply limits and high prices still restrict access.
Eli Lilly is preparing a rival pill, intensifying competition.
Injectables remain more effective for major weight loss, but tablets are expected to draw a broader group of users.
Analysts describe the shift from injections to pills as a pivotal moment for the industry.
